Excellent clinical and financial value are drivers for success in pharma, but without efficient, targeted pricing and adequate confidential contracting schemes, the success of any product is not ensured.1 A post on drug pricing by Joseph Jimenez, then CEO of Novartis, attracted a lot of attention in 2016.2 Jimenez stated: “We believe in the efficacy […]
Pharmaceutical tendering and contracting has long been common in healthcare for medical devices and diagnostics; the Gulf Cooperation Council and the Jamaica Commodity Trading Company have been using pharmaceutical tendering since the 1970s. In the 1990s, international institutions such as the World Health Organisation and the World Bank endorsed tendering as the preferred procurement process […]
Many policy makers, physicians and patients complain about the prices of new pharmaceutical products. The pharmaceutical industry has recognised this perception, and though industry associations and individual companies have tried to explain why pharmaceutical companies need to charge the prices they do, this is failing.